vagifem low estradiol 10 ug (as hemihydrate) modified release pessary blister pack
novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 10.3 microgram (equivalent: estradiol, qty 10 microgram) - pessary, modified release - excipient ingredients: macrogol 6000; magnesium stearate; lactose monohydrate; hypromellose; maize starch - vagifem low is indicated for the treatment of atrophic vaginitis due to oestrogen deficiency. vagifem low is not intended for children or males.
femoston 1/10 estradiol 1mg and estradiol 1mg with dydrogesterone 10mg tablet blister pack
viatris pty ltd - estradiol, quantity: 1 mg (equivalent: estradiol hemihydrate, qty 1.03 mg); dydrogesterone, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; hypromellose; maize starch; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uteri. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest possible effective dose for the shortest duration should be used with the goal being short term use.,hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uterus. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used with the goal being short term use (see dosage and administration and clinical trials). when prescribed solely for the prevention of postmenopausal bone mineral density loss in women, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of femoston should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing( see precautions and dosage and administration).
estradiol besins 0.75 mg/dose transderm. gel met. pump
besins healthcare sa-nv - estradiol hemihydrate 0,775 mg/dose - eq. estradiol 0,75 mg/dose - transdermal gel - 0,75 mg/dose - estradiol hemihydrate 0.775 mg/dose - estradiol
estradiol
viatris limited - estradiol hemihydrate 1.64mg; - transdermal patch - 100 mcg/24h - active: estradiol hemihydrate 1.64mg excipient: acrylic adhesive dipropylene glycol oleyl alcohol pegoterate polyolefin povidone silicone adhesive - estradiol is indicated for the following: - oestrogen replacement therapy for the treatment of the symptoms of natural or surgically induced menopause. - prevention of postmenopausal osteoporosis.
estradiol
viatris limited - estradiol hemihydrate 0.41mg; - transdermal patch - 25 mcg/24h - active: estradiol hemihydrate 0.41mg excipient: acrylic adhesive dipropylene glycol oleyl alcohol pegoterate polyolefin povidone silicone adhesive - estradiol is indicated for the following: - oestrogen replacement therapy for the treatment of the symptoms of natural or surgically induced menopause. - prevention of postmenopausal osteoporosis.
estradiol
viatris limited - estradiol hemihydrate 0.82mg; - transdermal patch - 50 mcg/24h - active: estradiol hemihydrate 0.82mg excipient: acrylic adhesive dipropylene glycol oleyl alcohol pegoterate polyolefin povidone silicone adhesive - estradiol is indicated for the following: - oestrogen replacement therapy for the treatment of the symptoms of natural or surgically induced menopause. - prevention of postmenopausal osteoporosis.
estradiol
viatris limited - estradiol hemihydrate 1.23mg; - transdermal patch - 75 mcg/24h - active: estradiol hemihydrate 1.23mg excipient: acrylic adhesive dipropylene glycol oleyl alcohol pegoterate polyolefin povidone silicone adhesive - estradiol is indicated for the following: - oestrogen replacement therapy for the treatment of the symptoms of natural or surgically induced menopause. - prevention of postmenopausal osteoporosis.
zoely nomegestrol acetate 2.5 mg and estradiol 1.5 mg tablet blister pack
theramex australia pty ltd - nomegestrol acetate, quantity: 2.5 mg; estradiol hemihydrate, quantity: 1.55 mg (equivalent: estradiol, qty 1.5 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; microcrystalline cellulose; purified talc; lactose monohydrate; colloidal anhydrous silica; titanium dioxide; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - oral contraception.
trisequens estradiol tablets and norethisterone acetate plus estradiol tablets dial dispenser pack
novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.07 mg (equivalent: estradiol, qty 2 mg); norethisterone acetate, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; hyprolose; purified talc; magnesium stearate; hypromellose; triacetin - short term symptomatic treatment of oestrogen deficiency associated with natural or artificial menopause (see dosage and administration and clinical trials).
estrofem estradiol (as hemihydrate) 2mg tablet dial dispenser pack
novo nordisk pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.07 mg (equivalent: estradiol, qty 2 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; purified talc; magnesium stearate; titanium dioxide; hypromellose; hyprolose; indigo carmine; macrogol 400 - short term symptomatic treatment of oestrogen deficiency due to natural or surgical menopause in hysterectomised postmenopausal women. in women with intact uteri, use of opposed therapy must be considered.